GlassScriptPhysician profile
Sweta Goel
NPI 1851680821
$1,871.56
in general payments reported to CMS, 2019-2025
41 companies · $273 in 2025
The $273 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $573 · 2020: $174 · 2022: $186 · 2023: $346 · 2024: $319 · 2025: $273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $939.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $938.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $204.81 | 2023-2025 | |
| Qapel Medical INC | $133.16 | 2025 | |
| Abbvie INC. | $123.23 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $122.93 | 2019-2024 | Austedo Xr, Austedo |
| Medtronic, INC. | $96.15 | 2023 | Solitaire X |
| Ge Healthcare | $93.29 | 2024-2025 | |
| Boston Scientific Corporation | $78.05 | 2023 | Watchman Flx |
| Acadia Pharmaceuticals INC | $75.02 | 2019-2020 | |
| Allergan, INC. | $74.41 | 2019-2020 | |
| Lundbeck LLC | $69.77 | 2019-2024 | Vyepti |
| Adamas Pharmaceuticals, INC. | $56.74 | 2019-2020 | |
| Sk Life Science, INC. | $49.27 | 2022-2023 | |
| Csl Behring | $46.68 | 2019-2020 | |
| Lilly USA, LLC | $46.32 | 2019-2025 | Kisunla |
| Biogen, INC. | $45.18 | 2020-2024 | Tysabri, Vumerity |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sweta Goel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.